Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients

Pediatric Pulmonology

Volumn 44, Issue 6, 2009, Pages 547-558

  Bjarnsholt, Thomas ^a,b   Jensen, Peter Østrup ^b   Fiandaca, Mark J ^c   Pedersen, Jette ^d   Hansen, Christine Rønne ^b   Andersen, Claus Bøgelund ^b   Pressler, Tacjana ^b   Givskov, Michael ^a   Høiby, Niels ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c AdvanDx Inc   (United States)

^d Bartholin Institute   (Denmark)

Author keywords

Biofilms; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

CARBENICILLIN; EOSIN; GENTAMICIN; HEMATOXYLIN; PEPTIDE NUCLEIC ACID; TOBRAMYCIN;

ARTICLE; BIOFILM; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAM STAINING; HUMAN; HUMAN TISSUE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY SYSTEM; SCHOOL CHILD; SPUTUM ANALYSIS;

ADOLESCENT; ADULT; BIOFILMS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NEUTROPHILS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; YOUNG ADULT;

EID: 67249099362     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21011     Document Type: Article

References (64)

1. Høiby N. Pseudomonas aeruginosaI Infection in Cystic Fibrosis [dissertation]. University of Copenhagen 1977. p. 1-96.
2. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980;28:546-556. (Pubitemid 10102095)
3. Doggett RG, Harrison GM, Carter RE, Mucoid Pseudomonas aeruginosa in patients with chronic illnesses. Lancet 1971;1:236-237.
4. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1974;82:551-558.
5. Pedersen SS, Høiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992;47:6-13.
6. Pedersen SS. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis. APMIS Suppl 1992;28:1-79.
7. Pedersen SS, Kharazmi A, Espersen F, Høiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun 1990;58:3363-3368. (Pubitemid 20293447)
8. Pedersen SS, Espersen F, Høiby N, Jensen T. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. J Clin Microbiol 1990;28:747-755. (Pubitemid 20123830)
9. Schiøtz PO, Nielsen H, Høiby N, Glikmann G, Svehag SE. Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection. Acta Pathol Microbiol Scand [C] 1978;86:37-40. (Pubitemid 8334042)
10. Döring G, Goldstein W, Botzenhart K, Kharazmi A, Schiotz PO, Høiby N, Dasgupta M. Elastase from polymorphonuclear leucocytes: a regulatory enzyme in immune complex disease. Clin Exp Immunol 1986;64:597-605. (Pubitemid 16122398)
11. Kronborg G, Shand GH, Fomsgaard A, Høiby N. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection. APMIS 1992;100:175-180.
12. Baltimore RS, Christie CD, Smith GJ. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis 1989;140:1650-1661.
13. Hoffmann N, Rasmussen TB, Jensen PO, Stub C, Hentzer M, Molin S, Ciofu O, Givskov M, Johansen HK, Høiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 2005;73:2504-2514. (Pubitemid 40470854)
14. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325. (Pubitemid 34141805)
15. Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003;36:230-240. (Pubitemid 37055971)
16. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von KG, Schmid KW, Weller M, Tummler B, Lang F, Grassme H, Döring G, Gulbins E. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14:382-391.
17. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R, Pare PD, Tiddens HA. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004;23:93-97. (Pubitemid 38088503)
18. Tiddens HA. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002;34:228-231. (Pubitemid 34971078)
19. Meyer KC, Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1536-1540. (Pubitemid 27505521)
20. West JB. Respiratory Physiology: The Essentials, 6th ed. Baltimore: Lippincott Williams & Wilkins; 2000.
21. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-721. (Pubitemid 39140629)
22. DeVries CA, Ohman DE. Mucoid-to-nonmucoid conversion in alginate-producing Pseudomonas aeruginosa often results from spontaneous mutations in algT, encoding a putative alternate sigma factor, and shows evidence for autoregulation. J Bacteriol 1994;176:6677-6687. (Pubitemid 24338083)
23. Ciofu O, Lee B, Johannesson M, Hermansen NO, Meyer P, Høiby N. Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology 2008;154:103-113. (Pubitemid 351201391)
24. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993;341:1065-1069. (Pubitemid 23114408)
25. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JI, Jensen P, Johnsen AH, Givskov M, Ohman DE, Molin S, Høiby N, Kharazmi A. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999;145:1349-1357. (Pubitemid 29294920)
26. Ciofu O, Riis B, Pressler T, Poulsen HE, Høiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005;49:2276-2282. (Pubitemid 40734454)
27. Szaff M, Høiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-657.
28. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol. 1999;28:159-166.
29. Høiby N, Frederiksen B. Microbiology of cystic fibrosis. In: Hodson ME Geeddes D editors. Cystic Fibrosis, 2nd ed. London, UK: Arnold; 2000. pp 83-107.
30. Johansen HK, Norregaard L, Gotzsche PC, Pressler T, Koch C, Høiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success? - A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol 2004;37:427-432. (Pubitemid 38620065)
31. Stender H. PNA FISH: an intelligent stain for rapid diagnosis of infectious diseases. Expert Rev Mol Diagn 2003;3:649-655. (Pubitemid 37101879)
32. Stender H, Broomer A, Oliveira K, Perry-O'Keefe H, Hyldig-Nielsen JJ, Sage A, Young B, Coull J. Rapid detection, identification, and enumeration of Pseudomonas aeruginosa in bottled water using peptide nucleic acid probes. J Microbiol Methods 2000;42:245-253. (Pubitemid 30759024)
33. Pedersen SS, Espersen F, Høiby N, Shand GH. Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 1989;27:691-699. (Pubitemid 19098106)
34. Johnson GD, Araujo GMCN. A simple method of reducing the fading of immunofluorescence during microscopy. J Immunol Methods 1981;43:349-350. (Pubitemid 11126350)
35. Lethem MI, James SL, Marriott C, Burke JF. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 1990;3:19-23. (Pubitemid 20046657)
36. Shah PL, Scott SF, Knight RA, Hodson ME. The effects of recombinant human DNase on neutrophil elastase activity and interleukin-8 levels in the sputum of patients with cystic fibrosis. Eur Respir J 1996;9:531-534. (Pubitemid 26117798)
37. Bjarnsholt T, Kirketerp-Moller K, Jensen PO, Madsen KG, Phipps R, Krogfelt K, Høiby N, Givskov M. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 2008;16:2-10.
38. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007;4:406-417. (Pubitemid 47330878)
39. Høiby N, Flensborg EW, Beck B, Friis B, Jacobsen SV, Jacobsen L. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis 1977;58:65-79.
40. Høiby N, Koch C. Maintenance treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Thorax 2000;55:349-350. (Pubitemid 30245687)
41. Høiby N. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1974;82:541-550.
42. Bauernfeind A, Bertele RM, Harms K, Horl G, Jungwirth R, Petermuller C, Przyklenk B, Weisslein-Pfister C. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 1987;15:270-277.
43. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002;34:232-236. (Pubitemid 34971079)
44. Potts SB, Roggli VL, Spock A. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatr Pathol Lab Med 1995;15:707-721.
45. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951.
46. Koch C, Høiby N. Diagnosis and treatment of cystic fibrosis. Respiration 2000;67:239-247.
47. Hansen CR, Pressler T, Koch C, Høiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005;4:35-40. (Pubitemid 40347775)
48. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, Elborn JS. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995-1001. (Pubitemid 351717594)
49. Anwar H, van Biesen T, Dasgupta M, Lam K, Costerton JW. Interaction of biofilm bacteria with antibiotics in a novel in vitro chemostat system. Antimicrob Agents Chemother 1989;33:1824-1826. (Pubitemid 19239184)
50. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-193. (Pubitemid 34303762)
51. Drenkard E. Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect 2003;5:1213-1219. (Pubitemid 37410254)
52. Bjarnsholt T, Jensen PO, Burmolle M, Hentzer M, Haagensen JA, Hougen HP, Calum H, Madsen KG, Moser C, Molin S, Høiby N, Givskov M. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005;151:373-383. (Pubitemid 40277742)
53. Bjarnsholt T, Kirketerp-Moller K, Kristiansen S, Phipps R, Nielsen AK, Jensen PO, Høiby N, Givskov M. Silver against Pseudomonas aeruginosa biofilms. APMIS 2007;115:921-928. (Pubitemid 47256284)
54. Landry RM, An D, Hupp JT, Singh PK, Parsek MR. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol Microbiol 2006;59:142-151.
55. Jensen PO, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, Christoffersen L, Moser C, Williams P, Pressler T, Givskov M, Høiby N. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007;153:1329-1338. (Pubitemid 46779989)
56. Christensen LD, van Gennip M, Jensen PO, Pamp S, Phipps R, Moser C, Alhede M, Tolker-Nielsen T, Høiby N, Givskov M, Bjarnsholt T. Quorum sensing controlled rhamnolipid production is crucial for the ability of Pseudomonas aeruginosa to evade the innate immune response in two different animal models of infection. Pediatr Pulmonol 2008;43:258.
57. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001;183:5395-5401. (Pubitemid 32802613)
58. Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Høiby N, Molin S. In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol 2008;190:2767-2776.
59. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996;271:64-67. (Pubitemid 26033276)
60. Pier GB, Grout M, Zaidi TS, Goldberg JB. How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Crit Care Med 1996;154:S175-S182. (Pubitemid 26346903)
61. Wyckoff TJ, Thomas B, Hassett DJ, Wozniak DJ. Static growth of mucoid Pseudomonas aeruginosa selects for non-mucoid variants that have acquired flagellum-dependent motility. Microbiology 2002;148:3423-3430. (Pubitemid 35414454)
62. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997;111:955-962. (Pubitemid 27171467)
63. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006;57:306-311. (Pubitemid 43160174)
64. Permin H, Koch C, Høiby N, Christensen HO, Moller AF, Moller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 1983;12:313-323.